1991 Apr 24.

Further clinical studies with an aldose reductase inhibitor in diabetic neuropathy.

CHDR

van Gerven JM

More related publications

Pharmacodynamic response profiles of anxiolytic and sedative drugs.

Chen X, Broeyer F, de Kam M, Baas J, Cohen A, van Gerven J, 2017 Apr 30

View publication
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.

Cruz HG, Hay JL, Hoever P, Alessi F, te Beek ET, van Gerven JM, Dingemanse J, 2014 Jul 31

View publication
Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol?

Kleinloog D, Liem-Moolenaar M, Jacobs G, Klaassen E, de Kam M, Hijman R, van Gerven J, 2012 Sep 30

View publication

Careers
News
Contact
Search

Clinical studies & Development
CHDR's story
People
Education
Library

Clinical development & Services

Therapeutic areas
Central Nervous System
Internal Medicine
Methods & Biomarkers
Central Nervous System
Internal Medicine
Imaging Techniques
Translational Biomarkers
Trial Services
CHDR InnoS

Participate in a Clinical Trial proefpersoon.nl

Browse 659 publications in the CHDR library

Clinical studies & Development
CHDR's story
People
Education
Library

Clinical development & Services

Therapeutic areas
Central Nervous System
Internal Medicine
Methods & Biomarkers
Central Nervous System
Internal Medicine
Imaging Techniques
Translational Biomarkers
Trial Services
CHDR InnoS

Participate in a Clinical Trial proefpersoon.nl

Browse 659 publications in the CHDR library

Partners

Sponsors
Collaborations

People

Supervisory board
Scientific advisory board
Governance

Social media

Facebook
Twitter
LinkedIn
Website by Just